Literature DB >> 9626057

Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy.

M Pérez1, J M Valpuesta, E M de Garcini, C Quintana, M Arrasate, J L López Carrascosa, A Rábano, J García de Yébenes, J Avila.   

Abstract

Tau-containing filaments purified from the brain of progressive supranuclear palsy (PSP) patients were isolated and characterized. These filaments co-purify with regular particles that biophysical and biochemical methods identified as ferritin shells. In vivo, brain tau accumulation in PSP co-localized with ferritin. These results suggest that ferritin/iron could modulate the formation of tau aggregates in PSP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626057      PMCID: PMC1858430     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

1.  Frequency of Alzheimer's neurofibrillary tangles in the cerebral cortex in progressive supranuclear palsy (subcortical argyrophilic dystrophy).

Authors:  H Ishino; S Otsuki
Journal:  J Neurol Sci       Date:  1976-07       Impact factor: 3.181

2.  Electron microscopic study of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome.

Authors:  S Roy; C K Datta; A Hirano; N R Ghatak; H M Zimmerman
Journal:  Acta Neuropathol       Date:  1974       Impact factor: 17.088

3.  Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome.

Authors:  I Tellez-Nagel; H M Wiśniewski
Journal:  Arch Neurol       Date:  1973-11

4.  Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy.

Authors:  M Tomonaga
Journal:  Acta Neuropathol       Date:  1977-02-28       Impact factor: 17.088

5.  Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy.

Authors:  S Yagishita; Y Itoh; N Amano; T Nakano; A Saitoh
Journal:  Acta Neuropathol       Date:  1979-10       Impact factor: 17.088

6.  Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles.

Authors:  M G Spillantini; R A Crowther; M Goedert
Journal:  Acta Neuropathol       Date:  1996-07       Impact factor: 17.088

7.  Neurofibrillary pathology in progressive supranuclear palsy.

Authors:  N R Ghatak; D Nochlin; M G Hadfield
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

8.  Immunocytochemical comparison of neurofibrillary tangles in senile dementia of Alzheimer type, progressive supranuclear palsy, and postencephalitic parkinsonism.

Authors:  S H Yen; D S Horoupian; R D Terry
Journal:  Ann Neurol       Date:  1983-02       Impact factor: 10.422

9.  The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy.

Authors:  O Bugiani; G L Mancardi; A Brusa; A Ederli
Journal:  Acta Neuropathol       Date:  1979-02-15       Impact factor: 17.088

10.  Progressive supranuclear palsy: clinico-pathological and biochemical studies.

Authors:  K Jellinger; P Riederer; M Tomonaga
Journal:  J Neural Transm Suppl       Date:  1980
View more
  24 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers.

Authors:  Ismael Santa-María; Félix Hernández; Mark A Smith; George Perry; Jesús Avila; Francisco J Moreno
Journal:  Mol Cell Biochem       Date:  2005-10       Impact factor: 3.396

Review 3.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 5.  The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications.

Authors:  George Perry; Lawrence M Sayre; Craig S Atwood; Rudolph J Castellani; Adam D Cash; Catherine A Rottkamp; Mark A Smith
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping.

Authors:  Kenji Ito; Chigumi Ohtsuka; Kunihiro Yoshioka; Hiroyuki Kameda; Suguru Yokosawa; Ryota Sato; Yasuo Terayama; Makoto Sasaki
Journal:  Neuroradiology       Date:  2017-07-08       Impact factor: 2.804

7.  Is tau a suitable therapeutical target in tauopathies?

Authors:  Elena Gomez de Barreda; Jesús Avila
Journal:  World J Biol Chem       Date:  2010-05-26

8.  The tau code.

Authors:  Jesús Avila
Journal:  Front Aging Neurosci       Date:  2009-07-30       Impact factor: 5.750

Review 9.  Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Authors:  Jesús Avila; Filip Lim; Francisco Moreno; Carlos Belmonte; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

10.  Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy.

Authors:  Jae-Hyeok Lee; Yong-Hee Han; Bok-Man Kang; Chi-Woong Mun; Sang-Jae Lee; Seung-Kug Baik
Journal:  J Neurol       Date:  2013-05-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.